STAT+ reported that Aurora Therapeutics, a startup building personalized gene-editing therapies, scrapped its lead program and cut staff just seven months after launching. The move follows competitive pressure in custom gene editing as Beam Therapeutics advanced a set of custom gene editors aimed at the same disease. Aurora’s spokesperson declined to disclose layoff counts or whether leadership remained, and the company did not publicly explain the scientific rationale behind the program termination. The episode highlights how quickly capital, execution, and competitive positioning can converge in personalized gene editing, where early differentiation and speed to evidence are critical to survival.